Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EBT: 2018-2024

Historic EBT for Eton Pharmaceuticals (ETON) over the last 7 years, with Dec 2024 value amounting to -$3.8 million.

  • Eton Pharmaceuticals' EBT fell 490.22% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 22.18%. This contributed to the annual value of -$3.8 million for FY2024, which is 452.69% down from last year.
  • Per Eton Pharmaceuticals' latest filing, its EBT stood at -$3.8 million for FY2024, which was down 452.69% from -$689,000 recorded in FY2023.
  • Over the past 5 years, Eton Pharmaceuticals' EBT peaked at -$689,000 during FY2023, and registered a low of -$28.0 million during FY2020.
  • Over the past 3 years, Eton Pharmaceuticals' median EBT value was -$3.8 million (recorded in 2024), while the average stood at -$4.5 million.
  • Its EBT has fluctuated over the past 5 years, first soared by 93.01% in 2021, then plummeted by 452.69% in 2024.
  • Over the past 5 years, Eton Pharmaceuticals' EBT (Yearly) stood at -$28.0 million in 2020, then skyrocketed by 93.01% to -$2.0 million in 2021, then crashed by 361.43% to -$9.0 million in 2022, then spiked by 92.36% to -$689,000 in 2023, then slumped by 452.69% to -$3.8 million in 2024.